A parenterally administered polysulfated glycosaminoglycans (PSGAG) productd has regulatory approval for the control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints. Independent studies support PSGAGs as safe and effective chondroprotectants with possible disease-modifying effects.92–94 The bioavailability and distribution of PSGAGs to inflamed joints in cats has been demonstrated with extralabel subcutaneous administration.95
d Adequan; Luitpold Pharmaceuticals, Inc., Animal Health Division,
The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat your pet’s health problem or disease without consulting with a veterinarian. Please consult your veterinarian with any questions or concerns you may have regarding your pet’s condition.